Entrada Therapeutics, Inc. (TRDA)
| Previous close | 14.19 |
| Open | 14.46 |
| Bid | 14.43 x 100 |
| Ask | 14.55 x 100 |
| Day's range | 14.40 - 14.81 |
| 52-week range | 10.62 - 18.44 |
| Volume | |
| Avg. volume | 79,370 |
| Market cap | 489.168M |
| Beta (5Y monthly) | -0.39 |
| PE ratio (TTM) | 21.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Entrada Therapeutics Reports First Quarter 2024 Financial Results
– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 – – Achieved $75 million milestone payment from Vertex for the clinical advancement of its Phase 1/2 clinical trial of VX-670 for DM1 – – Cash runway expected through the second quarter of 2026 with $327 million in cash, cash equivalents and marketable securities as of March 31, 2024 – BOSTON, May 07, 2024 (GLOBE NEWSWIRE) --
- GlobeNewswire
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for the second half of 2024 – – Regulatory applications expected in the fourth quarter of 2024 for the global Phase 2 clinical development of ENTR-601-44 and ENTR-601-45 in people living with DMD – BOSTON, Ma
- GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced it will participate in the following two investor conferences: Oppenheimer 34th Annual Healthcare Life Sciences Conference Dipal Doshi, Chief Executive Officer, will participate in a virtual fireside chat on We
